IOBT News and Press, IO Biotech Inc. From 05/23/22

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ® technology platform, announced today that the Company will be participating in the Jefferies ...

- First Patient Dosed in Proposed Registrational Trial in Melanoma - Multiple Sites to be Opened Across the United States, Australia, and Europe| - Trial Builds upon Phase 1 / 2 Results Recently Published in Nature Medicine NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- IO B...

IO Biotech press release (NASDAQ:IOBT): Q1 GAAP EPS of -$0.60. Cash and cash equivalents of $187.9m For further details see: IO Biotech GAAP EPS of -$0.60

-- Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma Presented at AACR in April -- -- Announced initiation and dosing of first patient in Phase 2 Trial of IOB102-IOB103 in combination with KEYTRUDA ...

Part 1: A New Way to Kill Tumors–IO102-IO103 Phase 3 Trial in Combination with Anti-PD-1 in Advanced Melanoma Thursday, April 28 th @ 12:30pmET NEW YORK, April 22, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical com...

IO Biotech (NASDAQ:IOBT) has begun a phase 2 trial of its non-small cell lung cancer candidate IO102-IO103. In the trial, the candidate will be combined with Merck's (MRK) Keytruda (pembrolizumab) in a first-line setting. The trial will also examine the combination in patients ...

NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win ® technology platform, announced today that it has dosed the first patient, in metastatic non-s...

IO Biotech (NASDAQ:IOBT) announced data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic Melanoma.  The company said the data from the trial showed three-year survival probability of 73% in patients with metastatic melanoma. IOBT reported the...

Updated Data as of December 1, 2021 from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic Melanoma Three-year Survival Probability of 73% Subgroup analyses including patients with poor prognosis NEW YORK, April 08, 2022 (GLOBE NEWSWIRE...

IO Biotech press release (NASDAQ:IOBT): FY Net loss was $67.9 million for the year ended December 31, 2021 compared to $12.0 million for the prior year period. Cash and cash equivalents of $211.5 million at December 31, 2021; cash runway sufficient to support operations through multiple data ...